Peter N. Van Rossum

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 161 publications

The limits of pooled evidence in early-stage NSCLC: are we comparing treatments or patients?

The limits of pooled evidence in early-stage NSCLC: are we comparing treatments or patients?

Journal: Lung cancer (Amsterdam, Netherlands)

Published: July 25, 2026

Definitive Chemoradiotherapy for Adenocarcinoma of the Esophagus or Esophago-Gastric Junction: A Dutch Population-Based Cohort Study.

Definitive Chemoradiotherapy for Adenocarcinoma of the Esophagus or Esophago-Gastric Junction: A Dutch Population-Based Cohort Study.

Journal: Annals of surgical oncology

Published: June 24, 2026

Ultra-hypofractionated versus conventional chemoradiation for newly diagnosed glioblastoma: Survival and toxicity results of a multicenter randomized trial.

Ultra-hypofractionated versus conventional chemoradiation for newly diagnosed glioblastoma: Survival and toxicity results of a multicenter randomized trial.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: June 16, 2026

Rescue by radiotherapy and anti-CTLA4/PD-1 after failure of anti-PD-1 therapy in patients with metastatic NSCLC: the phase II RECLAIM trial.

Rescue by radiotherapy and anti-CTLA4/PD-1 after failure of anti-PD-1 therapy in patients with metastatic NSCLC: the phase II RECLAIM trial.

Journal: Journal for immunotherapy of cancer

Published: June 03, 2026

Letter to the editor regarding 'Patient selection for proton therapy in lung cancer: Nationwide external validation and model update of a prognostic model for 2-year mortality including mean heart dose'.

Letter to the editor regarding 'Patient selection for proton therapy in lung cancer: Nationwide external validation and model update of a prognostic model for 2-year mortality including mean heart dose'.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: May 22, 2026

Rethinking Treatment Intent Beyond the Curative/Palliative Binary in Modern Oncology.

Rethinking Treatment Intent Beyond the Curative/Palliative Binary in Modern Oncology.

Journal: JAMA oncology

Published: April 23, 2026

Corrigendum to 'Oligometastatic disease in esophagogastric cancer: an update of recommendations on definition, diagnosis, and treatment': [Volume 2 - Issue C - 2023 2949-8198].

Corrigendum to 'Oligometastatic disease in esophagogastric cancer: an update of recommendations on definition, diagnosis, and treatment': [Volume 2 - Issue C - 2023 2949-8198].

Journal: ESMO gastrointestinal oncology

Published: April 17, 2026

Efficacy and safety of adrenalectomy and stereotactic ablative radiotherapy (SABR) for adrenal metastases: A systematic review and meta-analysis.

Efficacy and safety of adrenalectomy and stereotactic ablative radiotherapy (SABR) for adrenal metastases: A systematic review and meta-analysis.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: March 22, 2026

The survival impact of combining radiotherapy and immune checkpoint inhibitors in patients with solid tumors: A systematic review and living meta-analysis of randomized controlled trials.

The survival impact of combining radiotherapy and immune checkpoint inhibitors in patients with solid tumors: A systematic review and living meta-analysis of randomized controlled trials.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 17, 2026

Oligometastatic esophageal squamous cell carcinoma: a systematic review of current definitions and meta-analysis of local therapy outcomes.

Oligometastatic esophageal squamous cell carcinoma: a systematic review of current definitions and meta-analysis of local therapy outcomes.

Journal: Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus

Published: March 12, 2026

Quality of Chemoradiotherapy in Esophageal Adenocarcinoma Matters.

Quality of Chemoradiotherapy in Esophageal Adenocarcinoma Matters.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 05, 2026

The challenge of informed consent: Propensity score weighting to prevent selection bias.

The challenge of informed consent: Propensity score weighting to prevent selection bias.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: March 04, 2026

Showing 1-12 of 161

Last Updated: 09/26/2026